Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial
Background Surveillance on nasopharyngeal Streptococcus pneumoniae carriage in older children would be informative in determining whether a single priming and booster dose of pneumococcal conjugate vaccine (PCV) provides durable protection against pneumococcal disease compared with traditional dosin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2417856 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141398590423040 |
|---|---|
| author | Courtney P. Olwagen Alane Izu Lara Van der Merwe Lisa Jose Anthonet Koen Shabir A. Madhi |
| author_facet | Courtney P. Olwagen Alane Izu Lara Van der Merwe Lisa Jose Anthonet Koen Shabir A. Madhi |
| author_sort | Courtney P. Olwagen |
| collection | DOAJ |
| description | Background Surveillance on nasopharyngeal Streptococcus pneumoniae carriage in older children would be informative in determining whether a single priming and booster dose of pneumococcal conjugate vaccine (PCV) provides durable protection against pneumococcal disease compared with traditional dosing schedules.Methods and objectives We report on the secondary study objective to evaluate overall, vaccine-serotype (VT), and non-vaccine serotype (NVT) S. pneumoniae colonization at 3, 4, and 5 years of age in children who were randomized to receive 10-valent or 13-valent PCV formulations at 6 (6w + 1) or 14 (14w + 1) weeks compared with a two-dose primary series (2 + 1), with all children receiving a booster dose at 9 months of age, using a multiplex nanofluidic qPCR assay.Results The prevalence of overall, VT, or NVT at 5 years of age between the 2 + 1 compared with the 6w + 1 or 14w + 1 groups for both PCV10 and PCV13 did not differ.Conclusion Although inconclusive, our findings suggest that a reduced 1 + 1 PCV dosing schedule is unlikely to increase breakthrough cases of VT pneumococcal disease in older children, which can inform decision-making on transitioning to a 1 + 1 schedule in South Africa.Clinical trial registration: The trial is registered at www.clinicaltrials.gov (identifier is NCT04275284). |
| format | Article |
| id | doaj-art-1fe16186088c40d4ae74aecdf715b3b1 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-1fe16186088c40d4ae74aecdf715b3b12024-12-04T09:49:48ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-012311011101910.1080/14760584.2024.2417856Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trialCourtney P. Olwagen0Alane Izu1Lara Van der Merwe2Lisa Jose3Anthonet Koen4Shabir A. Madhi5South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South AfricaBackground Surveillance on nasopharyngeal Streptococcus pneumoniae carriage in older children would be informative in determining whether a single priming and booster dose of pneumococcal conjugate vaccine (PCV) provides durable protection against pneumococcal disease compared with traditional dosing schedules.Methods and objectives We report on the secondary study objective to evaluate overall, vaccine-serotype (VT), and non-vaccine serotype (NVT) S. pneumoniae colonization at 3, 4, and 5 years of age in children who were randomized to receive 10-valent or 13-valent PCV formulations at 6 (6w + 1) or 14 (14w + 1) weeks compared with a two-dose primary series (2 + 1), with all children receiving a booster dose at 9 months of age, using a multiplex nanofluidic qPCR assay.Results The prevalence of overall, VT, or NVT at 5 years of age between the 2 + 1 compared with the 6w + 1 or 14w + 1 groups for both PCV10 and PCV13 did not differ.Conclusion Although inconclusive, our findings suggest that a reduced 1 + 1 PCV dosing schedule is unlikely to increase breakthrough cases of VT pneumococcal disease in older children, which can inform decision-making on transitioning to a 1 + 1 schedule in South Africa.Clinical trial registration: The trial is registered at www.clinicaltrials.gov (identifier is NCT04275284).https://www.tandfonline.com/doi/10.1080/14760584.2024.2417856PCV10PCV13durable protectionStreptococcus pneumoniaenasopharyngeal colonization |
| spellingShingle | Courtney P. Olwagen Alane Izu Lara Van der Merwe Lisa Jose Anthonet Koen Shabir A. Madhi Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial Expert Review of Vaccines PCV10 PCV13 durable protection Streptococcus pneumoniae nasopharyngeal colonization |
| title | Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial |
| title_full | Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial |
| title_fullStr | Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial |
| title_full_unstemmed | Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial |
| title_short | Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial |
| title_sort | single priming and a booster dose of 10 valent and 13 valent pneumococcal conjugate vaccine pcv maintains suppression of vaccine serotype colonization in south african children at 3 4 and 5 years of age a single centre open labelled randomized trial |
| topic | PCV10 PCV13 durable protection Streptococcus pneumoniae nasopharyngeal colonization |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2417856 |
| work_keys_str_mv | AT courtneypolwagen singleprimingandaboosterdoseof10valentand13valentpneumococcalconjugatevaccinepcvmaintainssuppressionofvaccineserotypecolonizationinsouthafricanchildrenat34and5yearsofageasinglecentreopenlabelledrandomizedtrial AT alaneizu singleprimingandaboosterdoseof10valentand13valentpneumococcalconjugatevaccinepcvmaintainssuppressionofvaccineserotypecolonizationinsouthafricanchildrenat34and5yearsofageasinglecentreopenlabelledrandomizedtrial AT laravandermerwe singleprimingandaboosterdoseof10valentand13valentpneumococcalconjugatevaccinepcvmaintainssuppressionofvaccineserotypecolonizationinsouthafricanchildrenat34and5yearsofageasinglecentreopenlabelledrandomizedtrial AT lisajose singleprimingandaboosterdoseof10valentand13valentpneumococcalconjugatevaccinepcvmaintainssuppressionofvaccineserotypecolonizationinsouthafricanchildrenat34and5yearsofageasinglecentreopenlabelledrandomizedtrial AT anthonetkoen singleprimingandaboosterdoseof10valentand13valentpneumococcalconjugatevaccinepcvmaintainssuppressionofvaccineserotypecolonizationinsouthafricanchildrenat34and5yearsofageasinglecentreopenlabelledrandomizedtrial AT shabiramadhi singleprimingandaboosterdoseof10valentand13valentpneumococcalconjugatevaccinepcvmaintainssuppressionofvaccineserotypecolonizationinsouthafricanchildrenat34and5yearsofageasinglecentreopenlabelledrandomizedtrial |